David Einhorn Nuvation Bio Inc. Call Options Transaction History
Greenlight Capital Inc
- $1.97 Billion
- Q4 2023
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NUVB
# of Institutions
126Shares Held
107MCall Options Held
40.6KPut Options Held
2.9K-
Eco R1 Capital, LLC San Francisco, CA19.2MShares$58.4 Million1.99% of portfolio
-
Omega Fund Management, LLC Boston, MA14.1MShares$42.8 Million53.03% of portfolio
-
Black Rock Inc. New York, NY12.5MShares$38.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.53MShares$22.9 Million0.0% of portfolio
-
David Abrams Abrams Capital Management, L.P. | Boston, Ma3.81MShares$11.6 Million0.47% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $660M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...